PMDA drug package insert
レイボー錠50mg
PMDA Prescription drug · 日本イーライリリー株式会社 · package insert May 8, 2023
Key facts
| Brand names | レイボー錠50mg, レイボー錠100mg |
|---|---|
| Nonproprietary names | ラスミジタンコハク酸塩 |
| Companies | 製造販売元／日本イーライリリー株式会社, 販売元／第一三共株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 片頭痛治療剤 5-HT1F受容体作動薬 |
| Therapeutic category codes | 87119 |
| YJ codes | 1190030F1024, 1190030F2020 |
| Approval numbers | 30400AMX00003, 30400AMX00002 |
| Package insert edition | 第3版 |
| Package insert date | May 8, 2023 |
| PMDA document key | 530471_1190030F1024_1 |
| PMDA company code | 530471 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- Yes Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: